Yıl: 2017 Cilt: 18 Sayı: 5 Sayfa Aralığı: 328 - 333 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics

Öz:
Objective: This study compared the efficacy and safety of warfarin in specialized international normalized ratio (INR) outpatient clinic (INR-C) and in general cardiology outpatient clinic (General-C).Methods: Herein, 381 consecutive patients with a regular follow-up at INR-C (n=233) or General-C (n=148) for at least 1 year were retrospectively included. While INR-C patients were followed by a single experienced trained nurse, General-C patients were followed by a different cardiologist who worked in a rotational principle every month. During controls, demographic characteristics, INR levels, bleeding events, ischemic stroke, and transient ischemic attacks in the last 1 year were recorded. Primary endpoint was defined as the evaluation of the combined major bleeding and ischemic event, and secondary endpoint was defined as the evaluation of them separately.Results: The mean age of the patients was 62±12.86 and 43.8% were male. Mean time in therapeutic range (TTR) level was statistically higher in INR-C than that in General-C (68.8%±15.88 and 51.6%±23.04, respectively; p<0.001). Primary outcomes were significantly higher in General-C than that in INR-C [13.5% (20) and 6.4% (15); respectively, p=0.020]. Overall, major bleeding was observed in 25 patients (6.5%) and (2.6%) ischemic event was observed in 10 patients. In General-C patients, both major bleeding (8.8% vs. 5.2%; p=0.163) and the ischemic event (4.7% vs. 1.3%; p=0.051) were more, and no statistically significant differences were detected between the two clinics.Conclusion: The findings of our study demonstrate that patients followed in INR-C had higher TTR levels and lower bleeding and ischemic events rates that those followed in General-C.
Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.
  • 2. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Eng J Med 2003; 349: 1019-26.
  • 3. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167: 239-45.
  • 4. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the manage ment of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-47.
  • 5. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106: 968-77.
  • 6. Cove CL, Hylek EM. An updated review of target specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. J Am Heart Assoc 2013; 2: e000136.
  • 7. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-12.
  • 8. Cios DA, Baker WL, Sander SD, Phung OJ, Coleman CI. Evaluating the impact of study-level factors on warfarin control in US-based primary studies: a meta-analysis. Am J Health Syst Pharm 2009; 66: 916-25.
  • 9. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control:a systematic review and metaregression. Chest 2006; 129: 1155-66.
  • 10. Ertaş F, Kaya H, Kaya Z, Bulur S, Köse N, Gül M, et al. Epidemiology of atrial fibrillation in Turkey: preliminary results of the multicenter AFTER study. Turk Kardiyol Dern Ars 2013; 41: 99-104.
  • 11. Türk UO, Tuncer E, Alioğlu E, Yüksel K, Pekel N, Özpelit E, et al. Evaluation of the impact of warfarin's time-in-therapeutic range on outcomes of patients with atrial fibrillation in Turkey: Perspectives from the Observational, Prospective WATER Registry. Cardiol J 2015; 22: 567-75.
  • 12. Çelik A, İzci S, Kobat MA, Ateş AH, Çakmak A, Çakıllı Y, et al. The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR. Anatol J Cardiol 2016; 16: 595-600.
  • 13. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-962.
  • 14. Rosendaal FR, Cannegieter SC, Van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-9.
  • 15. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123: 2736-47.
  • 16. Demirbağ R, Sade LE, Aydın M, Bozkurt A, Acartürk E. The Turkish registry of heart valve disease. Turk Kardiyol Dern Ars 2013; 41: 1-10.
  • 17. Connock M, Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D, et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess 2007; 11: iii-iv, ix-66.
  • 18. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006; 367: 404-11.
  • 19. Heneghan CJ, Garcia-Alamino JM, Spencer EA, Ward AM, Perera R, Bankhead C, et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev 2016; 5: 7.
  • 20. Ansell J, Jacobson A, Levy J, Völler H, Hasenkam JM; International Self-Monitoring Association for Oral Anticoagulation. Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation. Int J Cardiol 2005; 99: 37-45.
  • 21. Fitzmaurice DA, Hobbs FD, Murray ET, Holder RL, Allan TF, Rose PE. Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing: a randomized, controlled trial. Arch Intern Med 2000; 160: 2343-8.
  • 22. Wilson SJ, Wells PS, Kovacs MJ, Lewis GM, Martin J, Burton E, et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ 2003; 169: 293-8.
  • 23. Hofmann E, Faller N, Limacher A, Méan M, Tritschler T, Rodondi N, et al. Educational Level, Anticoagulation Quality, and Clinical Outcomes in Elderly Patients with Acute Venous Thromboembolism: A Prospective Cohort Study. PloS One 2016; 11: e0162108.
  • 24. Arnsten JH, Gelfand JM, Singer DE. Determinants of compliance with anticoagulation: a case-control study. Am J Med 1997; 103: 11-7.
  • 25. Costa GL, Ferreira DC, Valacio RA, Vieira Moreira MdC. Quality of management of oral anticoagulation as assessed by time in therapeutic INR range in elderly and younger patients with low mean years of formal education: a prospective cohort study. Age Ageing 2011; 40: 375-81.
  • 26. Bertomeu González V, Anguita M, Moreno Arribas J, Cequier Á, Muñiz J, Castillo Castillo J, et al. Quality of anticoagulation with vitamin K antagonists. Clin Cardiol 2015; 38: 357-64.
  • 27. Cannegieter SC, Rosendaal FR, Wintzen AR, Van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-7.
  • 28. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
  • 29. Group SPiRITS. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42: 857-65.
  • 30. Investigators SPiAF. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-8.
  • 31. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Eng J Med 1996; 335: 540-6.
APA Kilic S, KEMAL H, Yüce E, Şimşek E, yağmur b, AKGÜL N, ÇINAR C, ZOGHİ M, GÜRGÜN C (2017). Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics. , 328 - 333.
Chicago Kilic Salih,KEMAL Hatice Soner,Yüce Elif ilkay,Şimşek Evrim,yağmur burcu,AKGÜL Nuray Memişoğlu,ÇINAR Cahide Soydaş,ZOGHİ Mehdi,GÜRGÜN Cemil Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics. (2017): 328 - 333.
MLA Kilic Salih,KEMAL Hatice Soner,Yüce Elif ilkay,Şimşek Evrim,yağmur burcu,AKGÜL Nuray Memişoğlu,ÇINAR Cahide Soydaş,ZOGHİ Mehdi,GÜRGÜN Cemil Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics. , 2017, ss.328 - 333.
AMA Kilic S,KEMAL H,Yüce E,Şimşek E,yağmur b,AKGÜL N,ÇINAR C,ZOGHİ M,GÜRGÜN C Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics. . 2017; 328 - 333.
Vancouver Kilic S,KEMAL H,Yüce E,Şimşek E,yağmur b,AKGÜL N,ÇINAR C,ZOGHİ M,GÜRGÜN C Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics. . 2017; 328 - 333.
IEEE Kilic S,KEMAL H,Yüce E,Şimşek E,yağmur b,AKGÜL N,ÇINAR C,ZOGHİ M,GÜRGÜN C "Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics." , ss.328 - 333, 2017.
ISNAD Kilic, Salih vd. "Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics". (2017), 328-333.
APA Kilic S, KEMAL H, Yüce E, Şimşek E, yağmur b, AKGÜL N, ÇINAR C, ZOGHİ M, GÜRGÜN C (2017). Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics. The Anatolian Journal of Cardiology, 18(5), 328 - 333.
Chicago Kilic Salih,KEMAL Hatice Soner,Yüce Elif ilkay,Şimşek Evrim,yağmur burcu,AKGÜL Nuray Memişoğlu,ÇINAR Cahide Soydaş,ZOGHİ Mehdi,GÜRGÜN Cemil Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics. The Anatolian Journal of Cardiology 18, no.5 (2017): 328 - 333.
MLA Kilic Salih,KEMAL Hatice Soner,Yüce Elif ilkay,Şimşek Evrim,yağmur burcu,AKGÜL Nuray Memişoğlu,ÇINAR Cahide Soydaş,ZOGHİ Mehdi,GÜRGÜN Cemil Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics. The Anatolian Journal of Cardiology, vol.18, no.5, 2017, ss.328 - 333.
AMA Kilic S,KEMAL H,Yüce E,Şimşek E,yağmur b,AKGÜL N,ÇINAR C,ZOGHİ M,GÜRGÜN C Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics. The Anatolian Journal of Cardiology. 2017; 18(5): 328 - 333.
Vancouver Kilic S,KEMAL H,Yüce E,Şimşek E,yağmur b,AKGÜL N,ÇINAR C,ZOGHİ M,GÜRGÜN C Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics. The Anatolian Journal of Cardiology. 2017; 18(5): 328 - 333.
IEEE Kilic S,KEMAL H,Yüce E,Şimşek E,yağmur b,AKGÜL N,ÇINAR C,ZOGHİ M,GÜRGÜN C "Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics." The Anatolian Journal of Cardiology, 18, ss.328 - 333, 2017.
ISNAD Kilic, Salih vd. "Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics". The Anatolian Journal of Cardiology 18/5 (2017), 328-333.